Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

July 15 (Reuters) - ProKidney Corp PROK.O:

• PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL

• PROKIDNEY CORP - FDA CONFIRMS EGFR SLOPE AS SURROGATE ENDPOINT FOR RILPARENCEL IN PATIENTS WITH CKD & TYPE 2 DIABETES

• PROKIDNEY CORP - TOPLINE DATA FOR ACCELERATED APPROVAL EXPECTED IN Q2 2027

• PROKIDNEY CORP - FDA CONFIRMS PHASE 3 PROACT 1 STUDY CAN BE USED FOR BOTH ACCELERATED APPROVAL & FOR FULL APPROVAL